Wednesday, September 7, 2016
Objective Capital Partners Adds CardioCell to Expanding Portfolio of Life Science Companies
Following Positive Results in Phase IIa Heart Failure Clinical Trial, CardioCell Chooses Objective Capital to Help Manage Rapid Growth
SAN DIEGO – Sept. 7, 2016 – Objective Capital Partners, a leading middle market investment bank and mergers and acquisition (M&A) advisory firm focused on transactions for companies with enterprise values up to $500 million, is pleased to announce that it has recently been retained by CardioCell LLC to help manage its growth needs. CardioCell, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, recently announced positive data from its Phase IIa clinical trial “Safety and Efficacy of Intravenous Infusion of Ischemia-Tolerant Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Cardiomyopathy” at the European Society of Cardiology (ESC) Congress and is currently planning a Phase III study in early 2017.
“CardioCell has just become the first company to demonstrate positive results using intravenously delivered mesenchymal stem cells to treat heart failure, and it’s a perfect match for Objective Capital’s portfolio of potential market disrupters in the life science space. We are pleased to help take CardioCell’s innovative biotechnology to the next level,” says David H. Crean, Ph.D., Managing Director of the Life Sciences practice at Objective Capital Partners.
CardioCell joins Objective Capital’s roster of biotechnology and life science clients, including public companies Marina Biotech and Regen Biopharma and several privately held enterprises. The Objective Capital team has extensive experience in the life science space working with companies on strategic advisory, sell- and buy-side engagements, licensing, valuation and capital funding efforts.
“Objective Capital has an exceptional understanding of the market opportunity for stem cell technology, and we are pleased to partner together as CardioCell enters an accelerated growth cycle,” says Sergey Sikora, CEO of CardioCell.
About CardioCell LLC
Founded in San Diego, California, in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the United States, Europe and the former Soviet Union. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction, chronic heart failure and peripheral artery disease. For more information, visit www.stemcardiocell.com.
About Objective Capital
Objective Capital Partners is a leading M&A advisory firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies with annual revenues up to $500 million. Services include sale transactions, equity and debt capital raises and comprehensive advisory services. The firm uses a proprietary process to work to achieve maximum company valuation, premium pricing, and high client satisfaction rates post-sale. The firm’s industry expertise includes: life sciences, business services, software and hardware technology, aerospace/defense, IT services, healthcare services, energy services, biotech, consumer products and specialized manufacturing. Additional information on Objective Capital Partners is available at www.objectivecp.com.
The above testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success. This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. David H. Crean and Channing Hamlet are Registered Representatives of BA Securities. Objective Capital Partners, LLC and BA Securities, LLC are separate and unaffiliated entities.